James R Armitage,
Senior Scientist
Having studied Biomedical Science at university, I worked briefly at AgrEvo, investigating agrochemical ADME and bioavailability. In 2000, I was afforded the opportunity to join Investigative Pre-Clinical Safety at SmithKline Beecham to develop predictive proteomic models of preclinical toxicity. Following the formation of GSK, I have continued to work within Investigative Safety Assessment until the present day. During this time I have the opportunity to expand into metabolomic/biochemical based safety assessment and toxicity prediction. In the last 5 years, I have had the good fortune (initially on secondment and now permanently) to work in a amazing group focussed on mitochondrial toxicity. In the Mitochondrial Group I head up work using metabolomics to develop in-vivo markers and measures of mitochondrial dysfunction that can routinely be applied to studies as NCEs pass through safety assessment.
|
|
|
